marketcap
Facebook
Twitter
Telegram
Report an ErrorQuarterly report 2022-Q3
added 11-07-2022
AVEO Pharmaceuticals Balance Sheet 2011-2024 | AVEO
Annual Balance Sheet AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|
Net Debt |
- | -48 M | -14 M | -5.39 M | 22.1 M | -1.09 M | -17.2 M | -31.7 M | -31.6 M | -50.1 M | -19.3 M |
Long Term Debt |
- | 12.7 M | 6.2 M | 15.8 M | 18.5 M | 11.9 M | 7.42 M | 8.93 M | 8.82 M | 19.2 M | 15.6 M |
Long Term Debt Current |
11 K | 369 K | - | - | - | - | - | - | - | - | - |
Total Non Current Liabilities |
- | 14.7 M | 14.6 M | 37 M | 58.8 M | 18.9 M | 10.9 M | 9.7 M | 45 M | 49.4 M | 36.9 M |
Total Current Liabilities |
18.7 M | 16.9 M | 21.1 M | 18.1 M | 32.1 M | 10.3 M | 12.4 M | 40.4 M | 31.4 M | 39.1 M | 34.6 M |
Total Liabilities |
59.5 M | 31.6 M | 35.8 M | 55.2 M | 91 M | 29.2 M | 23.3 M | 50.1 M | 76.4 M | 88.5 M | 71.5 M |
Deferred Revenue |
578 K | 1.97 M | 1.97 M | 1.66 M | 395 K | 510 K | 814 K | 537 K | 1.29 M | 1.29 M | 1.62 M |
Retained Earnings |
-675 M | -621 M | -586 M | -595 M | -587 M | -522 M | -495 M | -480 M | -427 M | -320 M | -206 M |
Total Assets |
105 M | 66.9 M | 50.6 M | 27.9 M | 50.2 M | 27.3 M | 40.5 M | 70.7 M | 146 M | 207 M | 295 M |
Cash and Cash Equivalents |
70.5 M | 61.8 M | 29.8 M | 24.4 M | 14.9 M | 15.1 M | 26.6 M | 52.3 M | 50.8 M | 76.1 M | 43.5 M |
Book Value |
45.9 M | 35.3 M | 14.8 M | -27.2 M | -40.8 M | -1.92 M | 17.2 M | 20.6 M | 69.9 M | 119 M | 224 M |
Total Shareholders Equity |
45.9 M | 35.3 M | 14.8 M | -27.2 M | -40.8 M | -1.92 M | 17.2 M | 20.6 M | 69.9 M | 119 M | 224 M |
All numbers in USD currency
Quarterly Balance Sheet AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Long Term Debt |
- | - | - | - | - | 19 K | 149 K | 261 K | 336 K | 336 K | 336 K | 336 K | 16.2 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10 M | 10 M | 13 M | 16 M | 18.9 M | 21.6 M | 21.6 M | 11.6 M | 11.6 M | 19.4 M | 21.8 M | 24.2 M | 26.5 M | 26.5 M | 26.5 M | 26.5 M | - | - | - | - | - |
Total Non Current Liabilities |
- | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Total Liabilities |
- | 72.4 M | - | 61.3 M | 59.5 M | 57.9 M | 52.8 M | 55 M | 31.6 M | 31.6 M | 31.6 M | 31.6 M | 35.8 M | 35.8 M | 35.8 M | 35.8 M | 55.2 M | 55.2 M | 55.2 M | 55.2 M | 91 M | 91 M | 91 M | 91 M | 29.2 M | 29.2 M | 29.2 M | 29.2 M | 23.3 M | 23.3 M | 23.3 M | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
Deferred Revenue |
- | - | - | - | 578 K | 1.07 M | 1.56 M | 1.97 M | 1.97 M | 1.97 M | 1.97 M | 1.97 M | 1.97 M | 1.97 M | 1.97 M | 1.97 M | 1.66 M | 1.66 M | 1.66 M | 1.34 M | 395 K | 395 K | 395 K | 481 K | 510 K | 510 K | 510 K | 510 K | 814 K | 814 K | 814 K | 814 K | 537 K | 537 K | 537 K | 537 K | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M | 1.29 M |
Retained Earnings |
- | -696 M | - | -685 M | -675 M | -667 M | -657 M | -643 M | -621 M | -621 M | -621 M | -621 M | -586 M | -586 M | -586 M | -586 M | -595 M | -595 M | -595 M | -595 M | -587 M | -587 M | -587 M | -587 M | -522 M | -522 M | -522 M | -522 M | -495 M | -495 M | -495 M | -495 M | -480 M | -480 M | -480 M | -480 M | -427 M | -427 M | -427 M | -427 M | -320 M | -320 M | -320 M | -320 M | -206 M | -206 M | -206 M | -206 M |
Total Assets |
- | 101 M | - | 98.2 M | 105 M | 109 M | 113 M | 127 M | 66.9 M | 66.9 M | 66.9 M | 66.9 M | 50.6 M | 50.6 M | 50.6 M | 50.6 M | 27.9 M | 27.9 M | 27.9 M | 27.9 M | 50.2 M | 50.2 M | 50.2 M | 50.2 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 40.5 M | 40.5 M | 40.5 M | 40.5 M | 70.7 M | 70.7 M | 70.7 M | 70.7 M | 146 M | 146 M | 146 M | 146 M | 207 M | 207 M | 207 M | 207 M | 295 M | 295 M | 295 M | 295 M |
Cash and Cash Equivalents |
- | 77.4 M | - | 73.8 M | 70.5 M | 68.8 M | 74.7 M | 121 M | 61.8 M | 61.8 M | 61.8 M | 61.8 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 50.8 M | 50.8 M | 50.8 M | 50.8 M | 76.1 M | 76.1 M | 76.1 M | 76.1 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M |
Book Value |
- | 28.8 M | - | 36.9 M | 45.9 M | 51.2 M | 60.2 M | 72.4 M | 35.3 M | 35.3 M | 35.3 M | 35.3 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | -27.2 M | -27.2 M | -27.2 M | -27.2 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -1.92 M | -1.92 M | -1.92 M | -1.92 M | 17.2 M | 17.2 M | 17.2 M | 40.5 M | 70.7 M | 70.7 M | 70.7 M | 70.7 M | 146 M | 146 M | 146 M | 146 M | 207 M | 207 M | 207 M | 207 M | 295 M | 295 M | 295 M | 295 M |
Total Shareholders Equity |
- | 28.8 M | 30.6 M | 36.9 M | 45.9 M | 51.2 M | 60.2 M | 72.6 M | 35.3 M | 35.3 M | 35.3 M | 35.3 M | 14.8 M | 14.8 M | 14.8 M | 14.8 M | -27.2 M | -27.2 M | -27.2 M | -27.2 M | -40.8 M | -40.8 M | -40.8 M | -40.8 M | -1.92 M | -1.92 M | -1.92 M | -1.92 M | 17.2 M | 17.2 M | 17.2 M | 17.2 M | 20.6 M | 20.6 M | 20.6 M | 20.6 M | 69.9 M | 69.9 M | 69.9 M | 69.9 M | 119 M | 119 M | 119 M | 119 M | 224 M | 224 M | 224 M | 224 M |
All numbers in USD currency